Indication: Type 2 diabetes
Sponsored by GlaxoSmithKline
Info:
A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the efficacy & safety of Albiglutide in Subjects with Type 2 diabetes. Albiglutide is a novel DPP-4 resistant GLP-1 once a week injection. It increases insulin secretion, decrease glucagon secretion and reduces appetite.
Inclusion Criteria:
- 18 years or older
- Diagnosed with Type 2 diabetes
- Having trouble controlling your blood sugar level
Indication: Type 1 & 2 diabetes
Sponsored by GENOMAS
Info:
Establishment of a clinical registry & DNA repository for personalized management of diabetes mellitus. Observational study. A single blood sample is obtained for each patient. DNA will be analyzed to identify genetic markers that are predictive of treatment response to glitazones that effect glucose and lipids.
Inclusion Criteria:
- Currently taking Avandia or Actos
Millions of people struggle to manage their Type 2 Diabetes.
Are you one of them?
Sponsored by Eli Lilly
Info:
Type 2 diabetes affects the quality of life for millions of adults. While sometimes diabetes can be controlled by exercise and diet, there are times when medication may be required. If you’ve been diagnosed with Type 2 Diabetes, consider taking part in a research study of an investigational medication for Type 2 Diabetes. Call (860) 224-5616 or visit
www.diabetesAWARDstudy.com for more information.
Inclusion Criteria
- Diagnosed with Type 2 Diabetes
